NCT02232529View on ClinicalTrials.gov

Pharmacokinetic Study of MIN-101 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Schizophrenia
Interventions
DRUG

MIN-101

DRUG

Placebo

Trial Locations (1)

NG116JS

Quotient Clinical, Ruddington, Nottingham

Sponsors
All Listed Sponsors
lead

Minerva Neurosciences

INDUSTRY